The aim of the study is to investigate the effect of magnetic resonance (MR) based online adaptive radiotherapy (RT) for treatment of low to intermediate risk localized prostate carcinoma (PCa) on the radiotherapy dose on the prostate and organs at…
Source
Brief title
Condition
- Reproductive neoplasms male malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Dose parameters D2cc of the bladder and prostate, which are an indication for
toxicity.
Secondary outcome
Not applicable.
Background summary
In recent years integrated MRI accelerator systems (e.g. MR-Linac (MRL)) have
been developed, enabling the use of superior soft-tissue contrast of MRI to
image the patient before and during radiotherapy delivery. The available MRI
accelerator systems combine a hybrid MRI and radiotherapy system (i.e. a linear
accelerator). These systems provide real-time soft-tissue imaging during
radiation delivery and as such allow tumor tracking for better targeting
precision. Due to the improved soft-tissue contrast compared to CBCT based RT,
MRI based RT enables the ability to perform daily adaptive re-planning on the
anatomy of the day. Deformation and rotation of the prostate gland result in
generous margins around the RT target area to ensure target coverage.
Therefore, daily adaptive re-planning with MR based RT could ensure more
effective tumor targeting while sparing the surrounding tissue as much as
possible due to the ability to adapt the radiotherapy plan to the daily (MRI
based) anatomy including all variations in prostate (and OAR) position,
including translations, rotations and deformations. The MRI accelerator systems
have the potential to offer high precision radiotherapy as a non-invasive
treatment of the prostate. Better targeting will possibly enable diminishing
radiotherapy margins, reducing toxicity and enabling future dose escalation to
increase tumor control rates.
Study objective
The aim of the study is to investigate the effect of magnetic resonance (MR)
based online adaptive radiotherapy (RT) for treatment of low to intermediate
risk localized prostate carcinoma (PCa) on the radiotherapy dose on the
prostate and organs at risk (OAR).
Study design
The study is a radiotherapy pilot planning study simulating the MR based RT
dose on the daily MRI-anatomy. Patients treated by standard EBRT for biopsy
confirmed low to intermediate risk localized PCa are asked to undergo 5
additional MRI*s (= study procedure) for the present dose planning study.
Patients will be recruited and asked for written informed consent by a
radiation oncologist at the Radiotherapiegroep (RTG) (The Netherlands). Both
the treatment and follow-up of the study subjects will be done according to the
standard of care by RTG. Modelling will be used for research purposes only.
Study burden and risks
Not applicable.
Wagnerlaan 47
Arnhem 6815AD
NL
Wagnerlaan 47
Arnhem 6815AD
NL
Listed location countries
Age
Inclusion criteria
Low to intermediate risk prostate carcinoma; scheduled for external beam
radiation therapy; meet all MRI safety criteria; written informed consent; over
18 years of age
Exclusion criteria
Transurethral resection of the prostate (TURP) in the last 3 months; hip
prosthesis
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL74822.091.20 |